HC Wainwright Reduces Earnings Estimates for Legend Biotech

Legend Biotech Co. (NASDAQ:LEGN) – Research analysts at HC Wainwright dropped their Q2 2025 earnings estimates for shares of Legend Biotech in a research report issued on Wednesday, November 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn $0.24 per share for the quarter, down from their previous estimate of $0.28. HC Wainwright has a “Buy” rating and a $73.00 price objective on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Legend Biotech’s Q4 2025 earnings at $0.12 EPS.

A number of other research analysts also recently weighed in on the company. Royal Bank of Canada reissued an “outperform” rating and issued a $86.00 target price on shares of Legend Biotech in a report on Tuesday, October 29th. Scotiabank boosted their target price on shares of Legend Biotech from $70.00 to $76.00 and gave the company a “sector outperform” rating in a research report on Monday, August 12th. Finally, Redburn Atlantic began coverage on shares of Legend Biotech in a research note on Tuesday, October 8th. They set a “buy” rating and a $86.00 price target on the stock. Thirteen equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $81.46.

Legend Biotech Stock Performance

LEGN stock opened at $38.19 on Thursday. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.98 and a quick ratio of 4.78. Legend Biotech has a 1 year low of $38.02 and a 1 year high of $70.13. The company has a market cap of $6.96 billion, a P/E ratio of -40.20 and a beta of 0.11. The stock’s fifty day moving average price is $46.01 and its 200-day moving average price is $48.23.

Legend Biotech (NASDAQ:LEGN) last issued its earnings results on Tuesday, November 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.22. The company had revenue of $160.20 million for the quarter, compared to analysts’ expectations of $143.91 million. Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.69%. The firm’s quarterly revenue was up 66.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.17) earnings per share.

Institutional Investors Weigh In On Legend Biotech

Institutional investors and hedge funds have recently bought and sold shares of the business. Public Employees Retirement System of Ohio purchased a new stake in shares of Legend Biotech during the third quarter worth about $229,000. Groupama Asset Managment grew its holdings in Legend Biotech by 20.2% during the 3rd quarter. Groupama Asset Managment now owns 27,374 shares of the company’s stock valued at $1,329,000 after buying an additional 4,592 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Legend Biotech during the 3rd quarter valued at approximately $458,000. XTX Topco Ltd purchased a new position in shares of Legend Biotech in the third quarter worth $1,840,000. Finally, State Street Corp lifted its holdings in shares of Legend Biotech by 0.4% in the third quarter. State Street Corp now owns 1,140,222 shares of the company’s stock worth $55,563,000 after buying an additional 4,735 shares in the last quarter. 70.89% of the stock is owned by institutional investors.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).